精优药业(00858)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00858 精优药业

休市中 11-06 15:58:46

0.050

+0.001

+2.04%

最高0.050	最低0.041	成交量369.00万
今开0.049	昨收0.049	日振幅18.37%
总市值1.45亿	流通市值1.45亿	总股本29.00亿
成交额16.87万	换手率0.13%	流通股本29.00亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00858","market":"HK","secType":"STK","nameCN":"精优药业","latestPrice":0.05,"timestamp":1793951926468,"preClose":0.049,"halted":0,"volume":3690000,"delay":0,"changeRate":0.020408163265306138,"floatShares":2900000000,"shares":2900000000,"eps":-0.3952,"marketStatus":"休市中","change":0.001,"latestTime":"11-06 15:58:46","open":0.049,"high":0.05,"low":0.041,"amount":168690,"amplitude":0.183673,"askPrice":0.05,"askSize":550000,"bidPrice":0.044,"bidSize":200000,"shortable":0,"etf":0,"ttmEps":-0.338,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":7,"adr":0,"listingDate":920995200000,"exchange":"SEHK","adjPreClose":0.049,"openAndCloseTimeList":[[1793928600000,1793937600000],[1793941200000,1793952000000]],"volumeRatio":1.131901840466493,"lotSize":10000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00858","defaultTab":"news","newsList":[{"id":"1155149710","title":"精优药业（00858）披露配售资金去向：1,960万港元投向电子模组制造 980万港元拓展贸易业务","url":"https://stock-news.laohu8.com/highlight/detail?id=1155149710","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155149710?lang=zh_cn&edition=full","pubTime":"2026-11-05 21:26","pubTimestamp":1793885195,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司11月5日发布配售补充公告，详细说明此前根据一般授权配售新股所得款项净额的具体用途。为进一步扩大业务规模，精优药业计划将配售事项的最高所得款项净额中约9,800,000港元用于采购电子模组及相关产品以供转售。在计划新设的制造业务方面，精优药业拟将约19,600,000港元用于建设年产能约100,000个电子模组的生产线，其中：。精优药业提醒，配售事项尚需满足既定条件方可完成，存在不确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195964493","title":"精优药业更新2026年10月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1195964493","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195964493?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:56","pubTimestamp":1793868964,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司于2026年11月5日发布了截至2026年10月31日的月度股份变动报告。根据公告，公司的注册股本规模保持在20,000,000,000股，每股面值为0.01港元，注册股本合计2亿港元，与上期一致。在员工股权激励方面，本月新增授出92,000,000份购股权，截至月末购股权结存总量增至168,500,000份。尽管购股权数量有所增长，但本月并未实际因行使期权而增发新股。公司确认，截至本月末，已符合适用的公众持股量要求，整体股本亦保持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197021822","title":"精优药业（00858）拟11月30日召开股东特别大会　审议20合1股份合并及减资方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1197021822","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197021822?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:52","pubTimestamp":1793868747,"startTime":"0","endTime":"0","summary":"1) 股份合并：每20股每股面值0.01港元的现有股份合并为1股面值0.20港元的合并股份；2) 向下圆整并处置合并产生的零碎股份，收益归公司；3) 股本削减：每股合并股份面值由0.20港元降至0.01港元，已发行股本将由约2,900万至4,030万港元削减至约145万至201.5万港元；5) 削减股本所获款项转入实缴盈余账户，用于抵销累计亏损或派息；6) 授权董事处理零碎股权及签署相关文件。公司董事会建议股东审慎投票，以推进资本结构优化及提升股份流动性。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196586167","title":"精优药业(00858)拟按0.052港元配售5.8亿股集资3,020万元 用于拓展电子模组业务","url":"https://stock-news.laohu8.com/highlight/detail?id=1196586167","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196586167?lang=zh_cn&edition=full","pubTime":"2026-10-30 22:56","pubTimestamp":1793372184,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司（00858）10月30日收市后公告，与配售代理盈立证券有限公司签订配售协议，拟按竭力基准向不少于六名独立承配人配售最多5.8亿股新股，配售价每股0.052港元。该配售价较当日收市价0.051港元溢价约1.96%，亦较紧接最后交易日前五个交易日平均收市价0.0494港元溢价约5.26%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155005860","title":"精优药业（00858）再次延迟债券第四次修订相关通函寄发及最后完成日期","url":"https://stock-news.laohu8.com/highlight/detail?id=1155005860","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155005860?lang=zh_cn&edition=full","pubTime":"2026-10-30 22:56","pubTimestamp":1793372167,"startTime":"0","endTime":"0","summary":"精优药业10月30日公告，为配合与债券条款及条件建议第四次修订相关事项，公司拟进一步延迟通函寄发时间及交易最后完成日期。基于上述原因，公司原定于2026年11月15日或之前寄发的通函将再度延后，最新预计寄发日期为2027年2月10日或之前。除上述延期外，第四份修订契据其他条款及条文维持不变并继续生效。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679243565","title":"精优药业(00858)拟溢价约1.96%配售最多5.8亿股 净筹约2940万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679243565","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679243565?lang=zh_cn&edition=full","pubTime":"2026-10-30 22:54","pubTimestamp":1793372081,"startTime":"0","endTime":"0","summary":"智通财经APP讯，精优药业 发布公告，于2026年10月30日，公司拟配售最多5.80亿股配售股份，占公司于本公告日期的现有已发行股本20%;及公司经发行配售股份扩大的已发行股本约16.67%。每股配售股份0.052港元的配售价较10月30日收市价每股0.051港元溢价约1.96%。假设根据配售协议配售最高数目的配售股份，配售事项所得款项总额将约为3020万港元，而所得款项净额将约为2940万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155613250","title":"精优药业（00858）授出共9,200万份购股权　涉三名执行董事及一名服务提供者","url":"https://stock-news.laohu8.com/highlight/detail?id=1155613250","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155613250?lang=zh_cn&edition=full","pubTime":"2026-10-21 22:31","pubTimestamp":1792593091,"startTime":"0","endTime":"0","summary":"2026年10月21日，精优药业控股有限公司公告称，董事会根据2022年9月2日采纳的购股权计划，向三名执行董事及一名服务提供者合共授出92,000,000份购股权，约占本公告日期已发行股份总数的3.17%。 授出日前五个营业日平均收市价0.0726港元；在本次授出后，购股权计划项下可供日后授出的股份数目为70,500,000股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109236335","title":"精优药业（00858）终止出售可换股债券谅解备忘录","url":"https://stock-news.laohu8.com/highlight/detail?id=1109236335","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109236335?lang=zh_cn&edition=full","pubTime":"2026-10-16 17:11","pubTimestamp":1792141895,"startTime":"0","endTime":"0","summary":"2026年10月16日，精优药业控股有限公司发布公告称，已向潜在买方发出书面终止通知，终止此前就可能出售可换股债券所签订的谅解备忘录。公司表示，由于与潜在买方的磋商未取得预期进展，董事会决定根据相关条款放弃进一步磋商。终止通知发出之日，谅解备忘录立即失效，双方不再享有任何权利或承担任何义务。董事会同时指出，谅解备忘录的终止不会对集团的财务状况及业务营运产生重大不利影响。此次终止标志着相关谈判正式结束。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675347307","title":"精优药业(00858.HK)建议实施股份合并、削减股本及股份拆细","url":"https://stock-news.laohu8.com/highlight/detail?id=2675347307","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675347307?lang=zh_cn&edition=full","pubTime":"2026-10-14 21:15","pubTimestamp":1791983732,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104182283","title":"精优药业（00858）公布二十合一股份合并并配套削减股本、股份拆细及调整买卖单位计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1104182283","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104182283?lang=zh_cn&edition=full","pubTime":"2026-10-14 21:02","pubTimestamp":1791982945,"startTime":"0","endTime":"0","summary":"10月14日，精优药业控股有限公司（00858）发布公告，董事会建议实施包括股份合并、削减股本及股份拆细在内的系列资本重组安排，并拟更改股份于联交所买卖的每手买卖单位。上述安排须获股东特别大会批准及满足若干条件后方可生效，预计于2026年12月2日生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159695619","title":"精优药业(00858)委任吴祥云为执行董事 月薪4万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159695619","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159695619?lang=zh_cn&edition=full","pubTime":"2026-10-12 22:31","pubTimestamp":1791815485,"startTime":"0","endTime":"0","summary":"精优药业10月12日公告称，公司已委任吴祥云为执行董事，自2026年10月12日起生效。自2026年8月起，吴先生已担任集团一家从事贸易业务的全资附属公司的总经理，并于2026年9月获委任为该附属公司董事。吴先生将任职至获委任后的首届股东周年大会，并可于届时参选连任，随后按公司章程轮值退任及竞选连任。此外，吴先生有权获授公司购股权，具体须经董事会及／或薪酬委员会批准。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199434417","title":"精优药业（00858）公布董事会及三大委员会最新构成","url":"https://stock-news.laohu8.com/highlight/detail?id=1199434417","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199434417?lang=zh_cn&edition=full","pubTime":"2026-10-12 22:31","pubTimestamp":1791815479,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司10月12日在香港发布公告，披露董事会最新成员名单及各委员会组成情况。公告显示，公司董事会由9名成员组成，包括5名执行董事及3名独立非执行董事。执行董事为谢毅博士（主席）、郭懿博士、程勇先生、王秀娟女士及吴祥云先生；独立非执行董事为金松女士、曾立博士及杨晓蓉女士。公告最后注明，相关任命自2026年10月12日起生效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674805533","title":"精优药业(00858)委任吴祥云为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2674805533","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674805533?lang=zh_cn&edition=full","pubTime":"2026-10-12 22:26","pubTimestamp":1791815164,"startTime":"0","endTime":"0","summary":"智通财经APP讯，精优药业(00858)公布，吴祥云先生已获委任为公司执行董事，自2026年10月12日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00858","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135408513","title":"精优药业更新9月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1135408513","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135408513?lang=zh_cn&edition=full","pubTime":"2026-10-05 16:35","pubTimestamp":1791189343,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司于2026年10月5日发布截至2026年9月30日的月度证券变动报告。报告显示，截至当月末，公司法定股本总额20,000,000,000股，相当于2亿港元，与上月持平。公司已发行股份总数仍为2,900,000,000股，期间未有任何新增发行或购回、注销及库藏股票活动。公司在公告中确认已符合香港联交所相关规则规定的公众持股量要求。本次公告由执行董事及公司秘书王秀娟签署。公司表示将继续遵守香港联交所《上市规则》和相关法律法规要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171945322","title":"精优药业（00858）再度延长第四份修订契据最后完成日期至2026年10月31日","url":"https://stock-news.laohu8.com/highlight/detail?id=1171945322","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171945322?lang=zh_cn&edition=full","pubTime":"2026-09-30 22:05","pubTimestamp":1790777131,"startTime":"0","endTime":"0","summary":"2026年9月30日，精优药业控股有限公司公告称，因需额外时间以达成先决条件，并考虑星太链股份自2026年5月6日上午9时起于香港联合交易所暂停买卖的情况，订约方已在2026年9月30日签署延期函件，将第四份修订契据的最后完成日期由2026年9月30日进一步延至2026年10月31日，或订约方可能协定的其他日期。本次延期后，除最后完成日期变更外，第四份修订契据的其他条款及条件维持不变并继续有效。该公告由公司董事会主席谢毅代表董事会发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186263411","title":"精优药业：Biowindow Gene Development (Hong Kong) Limited减持，好仓比例降至18.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186263411","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186263411?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:41","pubTimestamp":1789638067,"startTime":"0","endTime":"0","summary":"Biowindow Gene Development (Hong Kong) Limited于2026年9月16日以每股均价不详方式场外出售精优药业（00858）3.50亿股普通股，代价性质为现金。该笔为场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。Biowindow Gene Development (Hong Kong) Limited此次减持前持有精优药业好仓9.00亿股，占比31.03%；减持后持股量为5.50亿股，好仓比例降至18.96%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154686806","title":"精优药业：United Gene Group Ltd减持，好仓比例降至18.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154686806","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154686806?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:32","pubTimestamp":1789637561,"startTime":"0","endTime":"0","summary":"United Gene Group Ltd于2026年9月16日以场外交易方式出售精优药业3.50亿股，代价性质为现金，该笔交易未经联交所公开市场撮合，不属二级市场直接买卖。United Gene Group Ltd此次减持前持有精优药业好仓9.00亿股，占比31.03%；减持后持股量为5.50亿股，好仓比例降至18.96%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131020219","title":"精优药业：Biowindow Gene Development (Hong Kong) Limited减持，好仓比例降至18.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131020219","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131020219?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:24","pubTimestamp":1789637072,"startTime":"0","endTime":"0","summary":"Biowindow Gene Development (Hong Kong) Limited于2026年8月16日以场外交易方式（代价性质：现金）卖出精优药业（00858）3.50亿股，该笔交易并非在联交所公开市场直接买卖。Biowindow Gene Development (Hong Kong) Limited此次减持前持有精优药业好仓9.00亿股，占比31.03%；减持后持股量为5.50亿股，好仓比例降至18.96%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199775789","title":"精优药业：United Gene Holdings Limited减持，好仓比例降至18.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199775789","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199775789?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:23","pubTimestamp":1789637031,"startTime":"0","endTime":"0","summary":"United Gene Holdings Limited于2026年9月16日以场外现金方式出售精优药业（00858）股份3.50亿股。该笔为场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。United Gene Holdings Limited此次减持前持有精优药业好仓9.00亿股，占比31.03%；减持后持股量为5.50亿股，好仓比例降至18.96%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165164926","title":"精优药业（00858）：Ease Gold Investments Limited减持，好仓比例降至18.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165164926","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165164926?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:15","pubTimestamp":1789636501,"startTime":"0","endTime":"0","summary":"Ease Gold Investments Limited 于2026年9月16日在场外以现金方式出售精优药业（00858）3.50亿股普通股，属场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。Ease Gold Investments Limited 此次减持前持有精优药业好仓9.00亿股，占比31.03%；减持后持股量为5.50亿股，好仓比例降至18.96%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.extrawell.com.hk","stockEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":-0.3506},{"period":"3month","weight":-0.359},{"period":"6month","weight":-0.2537},{"period":"1year","weight":-0.4318},{"period":"ytd","weight":-0.3902}],"compareEarnings":[{"period":"1week","weight":0.051},{"period":"1month","weight":0.0146},{"period":"3month","weight":-0.0462},{"period":"6month","weight":-0.0724},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":-0.0448}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"精优药业控股有限公司是一家主要从事开发、制造及销售药品的投资控股公司。该公司主要通过三个分部运营业务。制造分部从事医药产品的开发、制造及销售业务。其自制产品包括转移因子口服溶液、贯新克及洲邦等。贸易分部从事进口药品的推广及经销业务。其进口产品包括美利巴及适今可。基因开发分部从事基因相关技术的商业开发及研发业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.407407,"avgChangeRate":0.054952},{"month":2,"riseRate":0.518519,"avgChangeRate":0.035392},{"month":3,"riseRate":0.296296,"avgChangeRate":0.026028},{"month":4,"riseRate":0.321429,"avgChangeRate":0.010323},{"month":5,"riseRate":0.392857,"avgChangeRate":0.096347},{"month":6,"riseRate":0.392857,"avgChangeRate":0.057621},{"month":7,"riseRate":0.25,"avgChangeRate":-0.039625},{"month":8,"riseRate":0.357143,"avgChangeRate":-0.034399},{"month":9,"riseRate":0.321429,"avgChangeRate":-0.023628},{"month":10,"riseRate":0.321429,"avgChangeRate":-0.002694},{"month":11,"riseRate":0.407407,"avgChangeRate":0.023994},{"month":12,"riseRate":0.296296,"avgChangeRate":-0.022304}],"exchange":"SEHK","name":"精优药业","nameEN":"EXTRAWELL PHAR"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"精优药业(00858)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供精优药业(00858)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"精优药业,00858,精优药业股票,精优药业股票老虎,精优药业股票老虎国际,精优药业行情,精优药业股票行情,精优药业股价,精优药业股市,精优药业股票价格,精优药业股票交易,精优药业股票购买,精优药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"精优药业(00858)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供精优药业(00858)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}